Konference: 2015 20th Congress of the European Hematology Association - účast ČR
Kategorie: Mnohočetný myelom
Téma: Publication only
Číslo abstraktu: PB1858
Autoři: Doc. MUDr.,Mgr. Jiří Minařík, PhD; MUDr. Zuzana Heřmanová, Ph.D.; MUDr. Pavla Petrová; MUDr. Petra Puščiznová; MUDr. Tomáš Pika; Doc.MUDr. Jaroslav Bačovský, CSc.; Mgr. Jana Zapletalová; Prof.MUDr. Vlastimil Ščudla, CSc.
Background
We performed a prospective study in patients with multiple myeloma
(MM) and monoclonal gammopathy of undetermined significance (MGUS)
aimed at the behavior of 13 selected parameters of myeloma bone
disease (MBD).
Aims
The aim of our study was to assess the behavior of selected
parameters of MBD with respect to therapeutic response.
Methods
Altogether we assessed a cohort of 51 patients: 31 patients with
newly diagnosed active MM who responded to treatment reaching at
least partial remission (PR) after 4 cycles of chemotherapy, 10
patients with refractory MM (progression or not reaching PR after 4
months), and two control groups – 5 patients with smoldering MM and
5 individuals with MGUS.
The selected parameters of MBD were
as follows: serum calcium (Ca), phosphorus (P), procollagen-I
N-terminal propeptide (PINP), carboxyterminal telopeptide of type I
collagen (ICTP), cross linked C-telopeptide (CTX), osteocalcin
(OC), parathormone (PTH), calcitonine (C), 25-hydroxyvitamin D
(D2), 1,25 dihydroxyvitamin D (D3), bone fraction of alkaline
phosphatase (bALP), sclerostin (Scl) and matrix metallopeptidase 9
(MMP9).
In the whole cohort we performed the analysis of MBD parameters at
the time of diagnosis (before start of chemotherapy in active MM)
and after 4 months. We assessed the behavior of the parameters with
respect to treatment response.
The patients were treated using bortezomib or thalidomide based
regimens. All patients with MBD received bisphosphonates and
adequte calcium support. In patients undergoing autologous stem
cell transplantation the follow-up results were acquired 4 months
after the diagnosis but before the transplantion.
For statistical estimation we used Wilcoxon pair test at p ? 0,05,
and McNemara test of symetry at p ? 0,05.
Results
We detected significant decrease of CTX (M 0,649 vs. 0,413ug/l; p =
0,014) and sclerostin (M 44,4 vs. 40,6pmol/l; p = 0,030) together
with significant increase of parathormone (M 26,0 vs. 60,0pmol/l; p
= 0,0005) after 4 months of therapy in patients responding to
initial treatment. All the other assessed parameters were without
significant change. In patients with refractory MM there was no
significant change in any of the assessed parameters. Similarly,
there was no significant change in any of the assessed parameters
in the control groups, i.e. in patients with smoldering MM, and
there was only boderline significant decrease of Ca (M 2,42 vs.
2,28 mmol/l; p =0,042) in MGUS individuals.
Summary
Despite appropriate anti-resorption therapy, there is no change in
the parameters of MBD in patients with MM who failed to respond
after 4 months of treatment. Patients who respond to therapy have
significant decrease of sclerostin and CTX suggesting their
auxiliary clinical potential in the assessment of bone turnover in
MM patients.
With support of NT14393.
Datum přednesení příspěvku: 12. 6. 2015